Liminal BioSciences To Sell Rare Pediatric Disease Priority Review Voucher For $105 Mln

(RTTNews) - Liminal BioSciences Inc. (LMNL) said that, its subsidiary Prometic Biotherapeutics Inc. or "PBT", agreed to sell its Rare Pediatric Disease Priority Review Voucher or "PRV" for US$105 million.

The PRV was granted by the U.S. Food and Drug Administration with the approval of Ryplazim (plasminogen, human-tvmh), for treatment of patients with plasminogen deficiency type 1 (hypoplasminogenia).

Under the terms of the previously announced Share Purchase Agreement entered into with Kedrion S.p.A dated June 22, 2021; Liminal Biosciences is entitled to retain an amount equal to 70% of the net sales proceeds of the sale of the PRV.